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Abstract 
OBP-301 (telomerase-specific replication-competent adenovirus with hTERT 
promoter) was constructed in a previous study and it showed a strong anti-cancer effect 
by inducing cell lysis in human lung and prostate cancer cells. This study investigated 
the effectiveness of a combination therapy of OBP-301 and Interleukin-2 (IL-2) in a 
mouse model of renal cell carcinoma (RCC). The cell-killing effect of OBP-301 was 
confirmed in vitro in the RENCA cancer cells. In in vivo experiment, 
luciferase-expressing RENCA cells were implanted in the left kidney and lung of 
BALB/c mice to prepare the RCC metastatic model. The animals were randomly 
divided into 4 treatment groups: PBS, IL-2 alone, OBP-301 alone, and the combination. 
The analyses of orthotopic tumor weight, lung metastasis, and luciferin-stained tumor 
images 14 days after each treatment showed significant tumor growth inhibition in the 
combination group in comparison to the OBP-301 or IL-2 treated groups. In addition, 
the percentage of regulatory T cells (Tregs) in the combination group was significantly 
suppressed in comparison to that in the PBS and single agent treatment groups. The 
outcomes of this study suggest that tumor-specific oncolytic immunovirotherapy may 
become an attractive strategy for the treatment of human RCC.  
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Introduction 
Renal cell carcinoma (RCC) has become the 4th most common genitourinary cancer 
with more than 51,000 new cases and about 13,000 cancer-specific deaths recorded per 
year in the United States.1 A considerable number of patients show distant metastasis at 
the time of diagnosis. Despite undergoing surgical treatment, chemotherapy, and 
radiotherapy, most of the RCC patients show disease progression and metastasis. 
Therefore, there is an urgent need for developing novel and effective therapies for RCC.  
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Telomerase is a ribonucleoprotein complex responsible for the complete replication 
of chromosome ends, and its activation is considered to play a crucial role in not only 
cell proliferation but also carcinogenesis.2,3,4,5 Previous studies have demonstrated an 
enhanced telomerase activity in more than 85% of human cancers, but only in a few 
normal somatic cells.3,4 Human telomerase reverse transcriptase (hTERT) positively 
regulates telomerase activity at the transcriptional level and is selectively overexpressed 
in proliferating neoplastic tissues and cells.2,3,4,5 Therefore, it seems reasonable to 
consider the hTERT promoter as a cancer-specific promoter. Previous study developed a 
unique strategy for oncolytic virotherapy based on the replicative capacity of the 
adenovirus by placing the envelope 1 (E1) gene under the control of a hTERT 
promoter.6,7,8,9,10 OBP-301 (Telomelysin®) -a cancer-selective replication-competent 
oncolytic adenovirus- can induce cell lysis in human non-small-cell lung cancer and 
prostate cancer cells.6,9 OBP-301 has the ability to replicate within tumors, enter the 
blood circulation, and then replicate in distant metastatic tumors after the intratumoral 
administration.9 
Interleukin-2 (IL-2) is a member of the immuno-cytokine family and was approved 
by Food and Drug Administration (FDA) of the United States for the treatment of 
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metastatic RCC.11 However, the overall response rates of the immunotherapy have been 
shown to be 6.5%.12 Due to the limited efficacy of IL-2 treatment, an effective treatment 
strategy that includes a combination of other methods is required for increasing the 
efficacy of IL-2 immunotherapy. The present study investigated whether a combination 
therapy of OBP-301 and IL-2 has enhanced anti-tumor and anti-metastatic effects in a 
mouse model of orthotopic RCC in comparison to OBP-301 or IL-2 therapy alone.  
5 
5 
 
Materials and Methods 
Animals 
Female BALB/c mice (6 to 8 week old) were purchased from SLC Inc., (Hamamatsu, 
JAPAN). They were maintained in a specific pathogen-free environment with free 
access to food and water at the laboratory animal center of Okayama University. They 
were allowed to adapt to their environment for more than 1 week before beginning the 
experiments. The animals were housed and handled in accordance with the Okayama 
University Animal Research Committee Guidelines.  
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Cell line 
The mouse RCC cell line (RENCA) was provided by the American Type Culture 
Collection (Rockville, MD). The RENCA cells were maintained in RPMI 1640 medium 
supplemented with 10% fetal bovine serum. The cells were cultured at 37°C in a 5% 
CO2 atmosphere and routinely passaged by trypsin-EDTA treatment in 100 cm2 flasks.  
 
OBP-301 and recombinant IL-2 protein 
OBP-301 (Telomelysin®, a tumor-specific replication-competent adenovirus) is a 
construct in which the hTERT promoter drives the expression of the E1A and E1B genes 
linked with an internal ribosome entry site.6,7 Before use, these viruses were purified by 
CsCl2 step-gradient followed by CsCl2 linear-gradient ultracentrifugation. Recombinant 
human IL-2 protein was kindly provided by Shionogi Co. (Osaka, JAPAN), and this 
protein was diluted in the culture medium just before use for the in vitro studies, and in 
phosphate-buffered saline (PBS) for the in vivo studies.  
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In vitro cell number assay 
RENCA cancer cells were seeded onto a 96-well plate at a density of 1000 cells/well. 
After 24 hours of incubation, the cells were treated with OBP-301 added at a 
multiplicity of infection (MOI) of 0.1, 1 and 10, or with recombinant IL-2 protein at 10, 
100 and 1000 units/ml. Further, RENCA cells were treated with 1 MOI of OBP-301 
mixed with 10, 100 and 1000 U/ml of IL-2. The in vitro cell-killing effect was analyzed 
by determining the cell number at the indicated time points using a cell proliferation kit 
of sodium 3´-[1-(phenylaminocarbonyl)- 3,4-tetrazolium]-bis (4-methoxy-6-nitro) 
benzene sulfonic acid hydrate (XTT) assay (Roche Diagnostics, Indianapolis, IN), 
according to the manufacturer’s instructions.  
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Imaging of RCC tumors in mouse 
The tumors derived from luciferase- stably transfected RENCA cells were imaged by 
the luciferase expression in the tumors. Briefly, the animals were anesthetized with 
isoflurane before and during imaging and then were injected intraperitoneally with 
luciferin (a substrate for luciferase) at 150 mg/kg in a volume of 100 μl. The animals 
were imaged at a peak time of 20 min post-luciferin injection via an IVIS-200 
instrument (Xenogen, Alameda, CA), using exposure times and sensitivity settings to 
avoid saturation. Image processing was done using the Living Image software program 
(Xenogen), by means of a region-of-interest analysis of the total photons per second for 
each tumor, with appropriate background subtraction.  
 
In vivo therapeutic experiments in the mouse RCC model 
The mouse model with orthotopic RCC tumors and metastatic lung tumors was 
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established in female BALB/c mice. Luciferase- stably transfected RENCA cells (5 × 
104 cells/100 μl PBS) were orthotopically injected into the subcapsular space of the left 
kidney and then 1 × 104 of the cells (in 100 μl PBS) were intravenously injected via the 
tail vein. At 10 days after the cell injection, tumor imaging was done and the mice were 
divided into 4 treatment groups [namely, PBS, IL-2, OBP-301, and the combination 
(OBP-301 plus IL-2)] according to the tumor burden. The mice were administered 
16000 units of recombinant IL-2 protein intraperitoneally or/and with OBP-301 (107 
PFU/100 μl) via the tail vein, on day 0, day 2 and day 4 of the treatment. In the PBS 
treatment group, 100 μl of PBS was injected both intraperitoneally and intravenously as 
the vehicle control. On day 14 after each treatment, tumor imaging was done and the 
tumor volume was analyzed in each mouse. The mice were then sacrificed and the 
weight of the orthotopic tumor in the left kidney and the bilateral lung tissue specimens 
with metastases were measured.  
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Flow cytometry 
For flow cytometry, 100 μl of blood sample from each mouse was collected in a 
plastic tube with ethylenediaminetetra-acetic acid (EDTA). The blood was then 
incubated with phycoerythrin-labeled anti-mouse CD4 antibody (eBioscience, San 
Diego, CA) and fluorescein isothiocyanate-labeled anti-mouse Foxp3 antibody 
(eBioscience) for 1 hour at 4°C. The labeled sample was washed twice with cold PBS. 
The sample was resuspended in 250 μl of cold PBS and analyzed using a 
fluorescence-activated cell sorter (FACS) Calibur flow cytometer (BD Biosciences, San 
Jose, CA) by gating on lymphocytes.13  
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 Histology and immunohistochemistry 
The mice were sacrificed for a histological analysis on day 14 after each treatment. 
The tissues were removed, fixed in formalin, embedded in paraffin, and sectioned. The 
5 μm sections were stained with hematoxylin and eosin and examined for histological 
changes. Immunohistochemistry was performed using a primary antibody against 
adenovirus type 5 E1A (BD PharMingen, San Diego, CA) to identify the 
OBP-301-infected tumor cells, as previously described.14,15 Briefly, the tumor tissue was 
excised, placed in the optimal cutting temperature (OCT) compound, and snap frozen in 
liquid nitrogen. The frozen sections (10 μm) were fixed in 4% paraformaldehyde in PBS 
for 30 minutes at room temperature (RT), washed, and permeabilized with PBS 
containing 0.1% Triton X-100. The endogenous peroxidase activity was blocked by 
incubating the sections in 3% hydrogen peroxide in methanol for 10 minutes. The 
sections were incubated with the primary antibody (1 : 50 dilution with PBS) at RT for 
16 hours and then with Histofine Simple Stain MAX PO (Nichirei, Tokyo, JAPAN) for 
30 minutes. Subsequently, the bound antibodies were detected using 
diaminobenzidine-tetrahydrochloride as the substrate and the sections were then 
counterstained with hematoxylin.  
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Statistical analysis 
The data are shown as the mean ± standard deviation. Unpaired Student’s t-test was 
performed for analyzing the statistical difference between any 2 groups. Differences 
were considered to be significant if the P value was less than 0.05.  
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Results 
In vitro anti-cancer efficacy of OBP-301 and IL-2 in RENCA cells 
The RENCA cells were infected with OBP-301 at the indicated MOIs to determine 
whether OBP-301 infection induces cancer cell-killing. At a MOI of 10, a significant 
reduction in RENCA cell number to less than 20% was observed on day 3 and day 4 
after OBP-301 treatment (Fig. 1a). Increasing concentrations of recombinant IL-2 
protein (10-1000 units/ml) did not contribute any anti-proliferative effects on RENCA 
cells (Fig. 1b). When RENCA cells were treated with 1 MOI of OBP-301 mixed with 
10, 100 and 1000 U/ml of IL-2, the addition of IL-2 did not enhance the cell-killing 
effect of OBP-301 (data not shown).  
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Potent anti-tumor effects of combined OBP-301 and IL-2 treatment on both orthotopic 
and metastatic tumors in the RCC mouse model  
The therapeutic efficacy of OBP-301 plus IL-2 treatment on the growth of RENCA 
cells was assessed in vivo. Luciferase-expressing RENCA cells were injected 
orthotopically and intravenously into immunocompetent mice to produce a mouse RCC 
model with an orthotopic tumor and metastatic lung tumors. Ten days after the cell 
injection, tumor luciferase-signaling was typically observed in the area of left kidney 
(Fig. 2a, [Before treatment (Day 0)]) using the IVIS instrument. Next, the mice were 
treated with one of 4 treatments [PBS, IL-2, OBP-301, and the combination (OBP-301 
plus IL-2)]. After 14 days of the treatment, the PBS treated mice showed a significant 
tumor growth, as estimated by IVIS (Fig. 2). OBP-301 administration induced more 
than a 50% reduction of tumor growth in comparison to the PBS group (Fig. 2b). The 
combination of OBP-301 plus IL-2 protein induced a potent tumor-inhibitory effect that 
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was statistically strong in comparison to that induced by the administration of each 
single agent. The tissue weight of the orthotopic tumor 14 days after the treatment 
revealed that the combination treatment induced a significant inhibition of the tumor 
growth in the kidney (Fig. 3a). The growth of metastatic lung tumors was also assessed 
in the treatment groups. After 14 days of treatment, the bilateral lungs were removed 
and the weight was measured. The PBS treated group, showed a large number of lung 
tumors on the surface (Fig. 3b). The increase of the lung weight was significantly 
suppressed in the OBP-301 and IL-2 combination group in comparison to the other 
groups, thus indicating the strongest inhibitory effects of the lung tumor growth (Fig. 
3b). The tissue weight of orthotopic tumor and lungs with metastatic tumor was 
correlated with the level of luciferase expression analyzed by IVIS between the 
treatment groups. 
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In vivo synergistic effect of OBP-301 treatment on the down-regulation of peripheral 
CD4+ Foxp3+ regulatory T cells by IL-2 administration 
The population of CD4+ Foxp3+ regulatory T cells (Tregs) is elevated in patients with 
progressive cancer and Tregs can thwart protective anti-tumor immunity.16,17,18 Recent 
human cancer trials suggest that depleting Tregs can be clinically beneficial.16,18 In 
order to explore the potential mechanisms underlying the potent anti-tumor effect 
elicited by the combination of OBP-301 and IL-2, the percentage of the CD4+ Foxp3+ 
regulatory T cells was assessed in the peripheral blood of each mouse. Blood was 
collected prior to initiating the treatment and on day 14 after the treatment. The 
percentage of CD4+ Foxp3+ T cells in the total lymphocytes was quantified by FACS 
analysis. The population of CD4+ Foxp3+ T cells was similar between all of the groups 
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before the treatment (Fig. 4). After 2 weeks of treatment, the percentage of CD4+ 
Foxp3+ T cells in the IL-2 treated group was reduced in comparison to that of the PBS 
treated mice (Fig. 4b). Furthermore, the population of CD4+ Foxp3+ T cells was 
significantly down-regulated in the combination group of OBP-301 and IL-2 treatment 
in comparison to that of the IL-2 treated group (Fig. 4b). The decrease in the percentage 
of peripheral CD4+ Foxp3+ T cells was observed only in the combination and IL-2 
groups.  
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Adenoviral E1A protein expression and tumor degeneration in an orthotopic tumor and 
metastatic lung tumors 
In order to investigate the effect of the OBP-301 action, the mice and tumors were 
histologically examined on day 14 after each treatment. An immunohistochemical 
analysis confirmed the expression of the adenoviral E1A protein in both the orthotopic 
RENCA tumor and metastatic lung tumors with OBP-301 treatment (Fig. 5a), 
indicating that intravenously administered OBP-301 spread via the blood circulation 
and distributed into the orthotopic and lung tumors. The E1A protein expression was 
not observed in the normal organs including the liver. A histopathological analysis 
revealed massive tissue degeneration in the orthotopic tumor and metastatic lung tumors 
of the OBP-301 and IL-2 combination group (Fig. 5b). Such tissue degeneration was 
not observed in the tumors of the PBS treated group. These findings provided consistent 
evidence for tumor volume reduction or growth inhibition observed after the combined 
treatment. In addition, the analysis of liver and other body tissue specimens indicated no 
histological damage in each treatment group (data not shown).  
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Discussion 
Oncolytic adenoviruses have been developed as a novel anti-tumor therapeutic 
strategy and their effectiveness is being currently tested in clinical trials.9 In order to 
improve the therapeutic index of anti-cancer agents, it is necessary that they selectively 
target cancer cells and spares the normal cells. Investigators have been focusing on 
developing such cancer-specific biochemical drugs.8,13 A replication-selective 
tumor-specific adenoviral agent, OBP-301 was constructed for the development of a 
cancer-specific therapeutic modality. OBP-301 has potent anti-cancer activities against 
many types of human malignancies such as lung, colon and prostate cancer.6,9 
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The in vitro assay with mouse renal cell carcinoma cells demonstrated the cytotoxic 
effect of OBP-301. On the other hand, no cytotoxic effect was induced by the IL-2 
treatment alone. It is reasonable because IL-2 will not be able to exhibit it's anti-cancer 
effects in the absence of the immune cells. In the in vivo experiment, intravenously 
administrated OBP-301 had significant cancer-killing effects in the both orthotopic 
renal tumor and metastatic lung tumors. There was no definite histological damage in 
the examined normal organs. In addition, the immunohistochemical examination 
disclosed the definite cancer selectivity because adenoviral E1A expression was clearly 
observed in the tumor tissue but not in the normal tissue. These results indicate that 
intravenously injected OBP-301 can specifically target the cancer tissue in the kidney 
and lung through the blood vessel and can replicate in the tumor. 
The current study revealed that the combined administration of intravenous OBP-301 
plus intraperitoneal IL-2 induced robust therapeutic effects on both the orthotopic renal 
tumor and metastatic lung tumors. To examine the anti-cancer immunomodulation in 
each mouse, the ratio of peripheral CD4+ Foxp3+ regulatory T cells (Tregs) was 
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measured by FACS analysis. Although there was no inhibitory effect of the Tregs 
population in the OBP-301 alone, the population of Tregs was significantly 
down-regulated after the OBP-301 and IL-2 combined therapy in comparison to the 
IL-2 alone group. Therefore, the in vivo synergistic effect of OBP-301 treatment on the 
IL-2 induced down-regulation of peripheral Tregs was observed in the current RCC 
model. This immunological synergistic effect in the suppression of Tregs may explain 
the robust anti-tumor therapeutic effects by the OBP-301 and IL-2 combination therapy. 
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IL-2 is a T cell growth factor that is thought to play a critical role in the regulation of 
T cell-dependent immune responses. High-affinity IL-2 receptor-mediated cell signaling 
is critical for the regulation of Tregs in vivo.18 Therefore, it appears that the therapeutic 
effect of IL-2 is at least partially due to the immunological activation by the 
down-regulated Tregs lymphocytes. In addition, a recent study showed that OBP-301 
virus-mediated oncolysis might be an effective stimulus for immature dendritic cells to 
induce specific response against cancer cells in humans.10 These findings may provide 
the clue to clarify the mechanism of synergistic anti-tumor immunological response 
elicited by the combination of OBP-301 and IL-2. 
In conclusion, the combined administration of OBP-301 and IL-2 exhibited a potent 
therapeutic effect in the model of RCC without any definite toxicities. These findings 
are noteworthy in terms of the clinical applications of this combination therapy for 
patients with both primary and metastatic renal cell carcinoma. The outcomes of this 
study also provide important implications regarding replication-selective oncolytic 
immunovirotherapy in human cancers.  
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Figure legends 
Figure 1 
In vitro cell-killing assay of OBP-301 and recombinant IL-2 protein in RENCA renal 
cancer cells.  
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(a,b) 
OBP-301 and IL-2 were added to the culture medium at the indicated concentration and 
then the cells were incubated for the indicated days. The relative cell number (%) is 
shown in comparison to the control group (no treatment). The number of experiments 
was ten. * : A significant difference was observed in comparison to the group with no 
treatment.  
 
Figure 2 
Anti-tumor effect of OBP-301 and/or IL-2 treatment on the growth of the orthotopic and 
lung RENCA tumors in BALB/c mice. 
(a) 
Bioluminescence images of five mice from each treatment group were shown on the 
indicated day. The animals with the tumors derived from luciferase- stably transfected 
RENCA cells were imaged after luciferin injection via an IVIS instrument. 
(b) 
The tumor volume was analyzed by IVIS after the indicated treatment. Tumor volume 
of each mouse was determined by region-of-interest analysis of total photons per second. 
Five mice were analyzed in each group. * : A significant difference was observed in 
comparison to the group with IL-2 alone and OBP-301 alone.  
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Figure 3 
Anti-tumor effect of OBP-301 and/or IL-2 treatment on the growth of the orthotopic and 
lung RENCA tumors in BALB/c mice. 
(a) 
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Representative macroscopic view of the resected orthotopic tumors is shown in the 
indicated treatment groups (upper panel). The tumor tissue weight (including normal 
kidney) was measured and analyzed between the groups. Twelve to fourteen mice were 
analyzed in the treatment groups. * : A significant difference was observed in 
comparison to the group of IL-2 alone and OBP-301 alone.  
(b) 
Representative macroscopic view of the resected lungs is shown in the indicated 
treatment groups (upper panel). The tumor tissue weight (including normal lung) was 
measured and analyzed between the groups. Twelve to fourteen mice were analyzed in 
the treatment groups. * : A significant difference was observed in comparison to the 
group of IL-2 alone and OBP-301 alone.  
 
Figure 4 
The percentage of peripheral CD4+ Foxp3+ regulatory T cells (Tregs) in the total 
lymphocytes was analyzed by FACS in each mouse. 
(a) 
The representative FACS data were shown. The blood sample was collected prior to 
initiating the treatment (day 0) and on day 14 after the treatment.  
(b) 
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The percentage of CD4+ Foxp3+ T cells in the total lymphocytes was quantified by 
FACS analysis and was shown in the indicated groups and treatment days. Five mice 
were analyzed in the treatment groups. * : A significant difference was observed in 
comparison to the group of IL-2 alone.  
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Figure 5 
Both histological and immunohistochemical analyses were performed on orthotopic and 
lung RENCA tumors. 
(a) 
The expression of adenovirus E1A protein in the orthotopic and lung RENCA tumors 
was examined by immunohistochemistry on day 14 after the indicated treatment. 
(b)  
Hematoxylin and eosin staining of the orthotopic and lung RENCA tumors on day 14 
after the indicated treatment.  
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